Medicine's $604 Billion "Memory Miracle"
We've just uncovered an amazing story about one man's recovery from one of the world's most dreaded… and expensive… diseases. His groundbreaking drug treatment could soon become widely available and dominate a $604 billion medical market.
And in March 2014, the entire world will find out why. The payoff to you could be astronomical… with triple-digit gains possible in one day. Here's how…
At the young age of 57, Walter Lewis was diagnosed with a terrifying disease.
A disease that steals away your most sacred possession… your sense of self.
A disease that strikes someone new every 68 seconds.
One many call the “defining disease of the baby boomers.”
One Walter knew all too well.
His mother had suffered from the same thing.
It’s an insidious disease that attacks the brain’s nerve cells, resulting in impaired memory, thinking, and behavior.
And Walter had watched as his mother’s quality of life deteriorated.
First her memory and thinking skills were destroyed… and eventually she was unable to even carry out the simplest tasks like eating and undressing.
And now the same fate awaited him.
Many of the things that made Walter who he was—traits, habits, knowledge, feelings, and memories—were already starting to fade away.
He was forgetting where his favorite coffee cup was, where he put his keys, the name of his favorite restaurant.
He was becoming moody, grumpy, and angry.
Married to him for 41 years, Walter’s wife Gloria didn’t know where to turn.
Walter was no longer the person she married. And sadly, he was turning into someone that Gloria no longer wanted to be with.
She knew she had to do something… and quickly.
That’s when she took Walter to the doctor.
And that’s when both their worst fears were realized: Walter was diagnosed with the same disease his mother suffered from…
A disease, according to the World Health Organization, that affects over 35 million people worldwide…
And costs the world over $604 billion per year to treat.
I call it “the silver plague,” because a staggering 1 out of every 3 seniors dies with some form of this disease.
And as the 76 million baby-boomer population continue to age, the numbers of those living with the brain-wasting disease will nearly triple.
It’s no wonder the National Institute on Aging calls this disease a “looming health epidemic.”
And the few drugs on the market that treat this disease—approved more than a decade ago—only target the symptoms of this degenerative brain disease and not the underlying cause.
Yet, even with their limited effectiveness, their combined sales last year topped $6 billion, according to BCC Research.
Analysts estimate that a treatment that targets the cause of the disease itself could generate sales of $20 billion or more.
As you probably know by now, the disease is Alzheimer’s.
ABC News recently reported that it’s “...the only one of the top 10 causes of death in America that cannot be prevented, cured or even slowed down once it begins.”
But that’s about to change…
Because in March 2014, one little-known biotech will release its biggest clinical results yet on a groundbreaking new Alzheimer’s treatment that could forever change the course of this terrifying disease.
It’s the first treatment ever to target the cause of Alzheimer’s… rather than just relieve the symptoms.
And it could become one of the biggest medical stories of the century.
That’s why I’m writing you today.
While we can’t guarantee what the clinical trial results will be in March…
We have a pretty good idea after uncovering Walter’s story…
Because Walter is currently participating in a trial study using this breakthrough new Alzheimer’s treatment.
His amazing story is a sneak preview of what this groundbreaking “memory miracle” treatment is capable of…
And the results are nothing short of spectacular.
That’s why I wanted to get the information to you right away, so you can get in early on this booming biotech before its March clinical trial results are released.
Because if the results are as positive as previous clinical trials, as I expect they will be, you could triple your investment in one day… or hold on and see 1,000% gains or more… I’ll explain how in just a moment.
But first, let’s get back to Walter’s incredible story of hope.
One Red Capsule Gives Walter His Memory…
And Life… Back
After his devastating diagnosis, Walter and his wife were desperate to find something… anything… that would slow down—let alone reverse—his increasingly debilitating symptoms.
That’s when they stumbled across a clinical study that was seeking volunteers for a new treatment for Alzheimer’s.
Desperate to save his vanishing memory, Walter signed up and was accepted.
And that’s when his amazing road to recovery from Alzheimer’s began.
Once a day he was given a red capsule—developed by this fledgling biotech—and within the first month, his memory started to return.
He started to remember little things like where his favorite cup was.
According to the investigator who’s overseeing the clinical trial, Walter’s improvement was simply “incredible.”
And over the next 14 months, he became a poster child for success in clinical trials.
Walter and his wife were elated. Walter called the breakthrough treatment “a godsend,” and his wife called it “amazing.”
Walter was finally on the road to getting his memory… and life… back.
Asked if the treatment changed his life, Walter said enthusiastically, “Absolutely.”
Walter’s story shares many of the same aspects as millions of others suffering from Alzheimer’s disease… like:
- Dick Swanson, 82, who’s been suffering from Alzheimer’s since his mid-70s. A former surgeon, his memory has been steadily declining, but at times still seems sharp. In an NBC interview, he said, “It just never occurred to me someday I would be a patient.”
- Dr. Don Myers, 73, a retired dermatologist, who chronicles his dance with the dreaded Alzheimer’s disease in a blog he calls The Trip Over. He shares his story on the Alzheimer’s Associated website, where he says, “I was getting angry a lot. I would fly off the handle at the grandkids.” He also got lost driving down familiar streets.
- Jeanne Johnson, 68, who’s been living with Alzheimer’s for over 12 years. She wrote a book about her struggle with Alzheimer’s. In it, she details her thoughts and emotions struggling with a suddenly unmanageable life; numerous hospitalizations, suicide attempts, everyday turmoil, and finally an extreme search for an accurate diagnosis of the illness responsible for it all.
And Walter’s extraordinary results from this groundbreaking new treatment brings new hope to these Alzheimer’s sufferers, along with millions of others who are desperately searching for a way to get their lives back.
Walter’s results reinforce what earlier clinical studies have already shown—that this disease-modifying treatment can:
- reverse memory loss
- improve cognition—which includes the activities of thinking, understanding, learning, and remembering, and
- slow the progression of this mind-wasting disease.
Even more good news…
Early clinical results suggest the treatment is safe and well tolerated.
It’s no wonder that the global medical community is holding its breath in anticipation of the March 2014 results from this tiny biotech…
As you can imagine, this booming biotech’s potential for profits is staggering.
You Could Make Life-Changing Gains
From This Breakthrough Alzheimer’s Discovery
Deutsche Bank estimates the market for this company’s breakthrough Alzheimer’s treatment could be worth $20 billion annually.
So we’re looking at a tiny biotech—$485 million market cap in early February—that’s set to dominate a $20 billion drug market with a one-of-a-kind, patented breakthrough treatment.
Even if it only captured a small 20% of this enormous potential( $4 billion), this booming biotech’s possible projected value would be enormous. If the company traded at just 1x its annual sales—well below the typical industry multiples of 2.5x to more than 5x—its shares would trade at about $98.
As I write you, the stock’s price is hovering around $11.28 per share; that’s a massive 769% potential gain from this tiny biotech that’s extremely undervalued at its current price.
A massive gain that could turn a $25,000 investment into $192,222 in the coming months.
Even if the price doubles between this letter and the expected results date—something I well expect to happen as Wall Street picks up on the potential—the gains on success would still be incredible.
It’s no wonder one leading financial service firm calls this tiny biotech an “unforgettable opportunity.”
This is money you could use to supplement your regular income, pay your mortgage, or take that exotic vacation to the South Pacific that’s on your bucket list.
And remember, that potential 769% gain is with only a minuscule 20% portion of the monster $20 billion market that Deutsch Bank is predicting, and at only a fraction of the multiple these stocks usually fetch.
Plus, that doesn’t take into account the potential windfall this tiny biotech could make as it adapts its breakthrough treatment to target Parkinson’s, Huntington’s, and various other brain diseases.
Or the fact that the competition is fading away…
Many big pharmaceutical companies have pulled the plug on their Alzheimer’s treatments, dumping hundreds of millions and not seeing any return.
CNBC reports that late in 2012, a highly anticipated Alzheimer’s drug that was a joint effort of Pfizer, Johnson & Johnson, and Elan was a huge failure, resulting in a loss of $700 million for J&J and $100 million for Elan.
After the failure, all three companies walked away from attempts to find an Alzheimer’s treatment.
This left the field wide open for a tiny innovator, like this little-known biotech, to enter and dominate the exploding Alzheimer’s market.
That’s why a 769% gain could be an extremely conservative estimate here.
But you must hurry…
You want to get in early before the NEXT catalyst we’re expecting from this company takes place: clinical trial results in March 2014, where you could see explosive gains happen quickly—even overnight…
With triple-digit gains possible in one day. It’s been done before…
When Spherix Inc. received FDA approval to start its final phase of testing for its new diabetes treatment, Naturlose, its stock nearly tripled in one day… going from $1.26 a share to $3.75.
Or when Intercept Pharmaceuticals recently jumped from $72.39 all the way to $275.87—a 281% one-day gain—on news that it was ending its clinical trial for a cirrhosis drug early because patients showed significant improvement. The company believed more testing would only keep the cure from the millions who need it today.
Right now is a perfect opportunity for you to get in early and maximize your gains on this Alzheimer's breakthrough before mainstream investors come onboard…
That’s why I urge you to let me send you a report I just finished, Extraordinary Wealth from Breakthrough Alzheimer’s Research.
Inside this exclusive report, I give you the full story on this tiny biotech and its incredible potential.
I’ll also give you the rest of our research that shows how this innovative biotech is not only making great strides in treating Alzheimer’s, but also has a library of more than 900 other compounds under research to potentially treat various diseases.
Can you see the massive opportunity here?
In short, by March 2014 we’re expecting an announcement from this fast-growing biotech that could signal the beginning of the end for Alzheimer’s…
Which could alleviate an immeasurable amount of human misery.
And is set to make billions.
And along the way, it could make fortunes for its early backers.
Why not you?
I’ll give you all the details on how to get this report for FREE in just a moment.
But first, let me introduce myself and share with you more details on this life-changing opportunity.
Your Guide to Extraordinary Technology Breakthroughs
I’m Alex Daley.
Today, as chief technology investment strategist at Casey Research, I profile technology companies that I believe have the best prospects of returning superior gains with the least amount of risk for my readers.
Perhaps you’ve seen me as a featured guest on CNN, CNBC, CBS World News, BBC, or one of many other networks that cover cutting-edge technology breakthroughs.
I’ve spent my career working in the trenches of the technology sector, often helping startups build their new technology.
As a teenager, I was helping create software for the Palm line of devices from US Robotics.
And since then, I’ve been involved in helping fill some of the biggest technology needs in the world:
- I helped MySpace work on music-streaming services and its local applications
- I consulted with Facebook to develop its data center and its photo application
- I helped construct a lie detector the CIA uses that measures the vibrations of a person’s vocal cords from across the room
I also worked inside of the executive suite at one of the biggest tech companies in the world, Microsoft… becoming a top strategist in its research and development headquarters.
I’m not telling you this to brag… but so that you know that I understand the technology industry inside and out, because I’ve worked at all phases of tech development.
And in all my years of researching and writing about innovative breakthroughs, I’ve rarely been as excited as I am about the revolutionary Alzheimer’s treatment that I’m sharing with you today.
This is a new technology that could transform how Alzheimer’s is treated and make early investors incredible, life-changing wealth.
Like when biotech innovator Vanda Pharmaceuticals released its game-changing schizophrenia drug Fanapt—investors watched as their shares soared 1,349% in less than a month.
This tiny biotech is set to join the rare ranks of history-making biotechnology companies that have discovered world-changing medical advances.
A discovery that is at the forefront of a new approach to treating, and eventually curing, Alzheimer’s.
I give you the full story in Extraordinary Wealth from Breakthrough Alzheimer’s Research.
But before I tell you how to secure your copy of this powerful report for FREE, let me share with you a few more details about what differentiates this little biotech’s revolutionary new Alzheimer’s treatment from the competition.
A Light at the End of a Long, Dark Tunnel…
Despite the increasing incidence of Alzheimer’s due to an aging population, no one has yet come up with a cure.
In fact, there are just five FDA-approved treatments to treat Alzheimer’s, and none of them is particularly effective.
According to a stark appraisal from Consumer Reports Health, “When compared to a placebo, most people who take one will not experience a meaningful benefit.”
And none of the treatments currently available makes any attempt to cure Alzheimer’s or stop the progression of the disease.
They are only intended to slow a person’s mental decline and alleviate some of the symptoms for a short period of time.
In fact, according to the Alzheimer’s Association, the current Alzheimer’s treatments are effective for only about six to twelve months, and then only in approximately half of the individuals who take them.
Recent activity on the research front hasn’t been especially encouraging, either.
In less than a year, three high-profile therapies from Big Pharma companies—Eli Lilly, Pfizer, and Baxter International—went belly-up due to failure to meet cognitive goals and preserving functional abilities in patients.
But I did find a bright light at the end of this particularly dark, seemingly endless tunnel.
As mentioned earlier, it comes in the form of a tiny biotech that is doing cutting-edge research in the field.
Keeping Alzheimer’s at Bay
The biotech’s point of attack involves a new approach from past treatments… something called beta-amyloid oligomers.
That’s a mouthful.
But put as simply as possible, beta-amyloid is a common protein fragment that has a strong tendency to clump.
As more and more of these fragments stick together, they’re collectively called oligomers.
Researchers now believe that beta-amyloid oligomers may be the main culprits in Alzheimer’s.
And the goal of this breakthrough new Alzheimer’s treatment is to prevent the beta-amyloids from clumping and creating the toxic oligomers that inhibit neurotransmission in the brain, with the result being rapid cognitive improvement.
So far, clinical results have been hugely successful…
With the breakthrough Alzheimer’s treatment successfully clearing both Phase I and Phase IIa of its FDA clinical trials with flying colors.
These early clinical results found the treatment to be safe, well tolerated, and showing a rapid improvement in cognition in Alzheimer’s patients.
Professor Greg Finch of the Mental Health Research Institute in Australia says this powerful new Alzheimer’s treatment could keep the disease at bay or delay its onset for “many years.”
Plus, early laboratory trials showed that the treatment reverses memory loss in normal aged mice—an incredible breakthrough that, if duplicated in humans in the current trial, only builds the franchise’s value further.
This could be an important first step in bringing an end to one of the world’s most dreaded diseases.
And a rare opportunity for you to land 1,000+% gains from a revolutionary new Alzheimer’s treatment that could change the course of medical history.
The stakes in this particular arena are high, obviously.
The potential payout for an effective, first-to-market therapy for Alzheimer’s is huge.
Consequently, the competition is fierce.
It’s no surprise that there are upwards of 40 other Alzheimer’s treatments in mid- to late-stage trials.
But most are based on therapies that have had limited effectiveness in the past…
The tiny biotech investigating toxic beta-amyloid oligomers is a medical pioneer on its own.
And its revolutionary new Alzheimer’s treatment could crack the code on the dreaded “silver plague.”
March 2014: Your Deadline for 769% Gains
Right now, in the form of this largely unknown biotech company, you could score gains of 769%… or more… as mainstream investors get a whiff of its life-changing Alzheimer’s treatment.
It’s a breakthrough treatment which is entering a market with an enormous unmet medical need, where existing treatments are not very effective, giving it relatively competition-free revenue potential for its innovative treatment.
Add in the fact that Alzheimer’s cases are expected to nearly triple within the foreseeable future as the baby-boomer population explodes:
… and what you get is an opportunity that is much more than investment worthy… it could literally change your life.
Best of all: the rights to this patented treatment belong to only this one tiny biotech.
And since there’s an urgent need for an Alzheimer’s treatment that’s even moderately effective, decent clinical trial results from this tiny company could lead to a fast-track FDA approval.
So far, research for Alzheimer’s has been a patchwork quilt of different approaches.
And since we don’t fully understand what causes the disease, development of an effective treatment has been daunting.
It’s involved a lot of guesswork, and Big Pharma has seen some spectacular flameouts.
As I mentioned earlier, none of the currently approved drugs makes any attempt to cure Alzheimer’s or stop the progression of the disease; they’re only intended to alleviate some of the symptoms for a short period of time.
Nevertheless, despite their limited amount of success, these drugs posted some impressive sales figures before cheaper generics became available…
- Aricept—the only drug currently approved for all stages of Alzheimer’s disease—is expected to post sales of just over $1 billion in 2013, after peaking at more than $3.5 billion annually in 2009.
- Forest Pharmaceuticals’ Namenda quickly became Aricept’s biggest competitor after it was approved in 2003, generating $750 million in sales in 2005.
- Novartis’ Exelon produced about $500 million in sales in 2005; that figure had doubled to $1 billion by 2010.
- Razadyne has seen slow but steady sales growth, from about $450 million in 2005 to $600 million in 2011; those aren’t figures to scoff at.
Huge numbers, but nothing compared to the massive $20 billion annually analysts at Deutsche Bank estimate the Alzheimer’s market is worth.
This biotech’s groundbreaking Alzheimer’s treatment can capture a significant chunk of that market, since its drug targets the cause of the disease… rather than just treating the symptoms.
It’s a huge step forward in the fight against this devastating disease, and a rare opportunity for you to get in early on a booming biotech that’s set to make billions off its discovery.
But you must hurry and get in before the next catalyst for this biotech company takes place—in March 2014—when the latest clinical tests results are released to the public.
Because once the mainstream media and average investors get hold of the potential multibillion-dollar profit-making ability of this revolutionary new Alzheimer’s treatment, your chances of maximizing your profits will quickly disappear.
That’s why I was excited to put together this exclusive report, Extraordinary Wealth from Breakthrough Alzheimer’s Research: so that you can get in early on this transformational medical breakthrough and find out the full details on the tiny biotech that discovered it.
And if my current winning track record is any indication of the coming success of my newest recommendation, you could soon add thousands of dollars of investment income to your bottom line.
Your Path to Lasting Technology Wealth
When I was offered the opportunity to head up a technology newsletter at Casey Research, I jumped at it.
Today, that newsletter has grown to be one of the most respected private investment advisory publications in the technology industry: Casey Extraordinary Technology.
The idea behind this service is to find the most promising, up-and-coming, new public technology companies for investors.
This allows investors to get into the emerging tech trends before they cross the chasm into the mainstream.
This way, once the herd catches on and investors start bidding up the share price, Casey Research readers are already positioned and ready to take profits.
And Casey Extraordinary Technology’s system is working… with readers enjoying a long list of winning recommendations.
In 2012, I closed out 11 positions, 10 of which were winners. That's a 91% win rate!
Some of the winners included:
|3D Systems Corp.||48%|
|Genomic Health Inc.||96%|
|Activision Blizzard Corp.||13%|
|Amylin Pharmaceuticals Inc.||50%|
In 2012, the Nasdaq gained about 16%, whereas my average gain per closed recommendation was 71%.
In 2013, l closed eleven positions that have lined readers’ pockets with potentially tens of thousands of dollars… including:
|Alnylam Pharmaceuticals Inc.||127%|
|Cisco Systems Inc.||9%|
|Isis Pharmaceuticals Inc.||147%|
|Seattle Genetics Inc.||108%|
If you had invested a mere $10,000 in each of these recommendations and closed out with me, you’d be sitting on an impressive pre-tax total gain of $103,200 today.
Whenever I tell subscribers to buy any investment, I make sure that the company meets my strict requirements.
It needs to be developing something that will be in demand no matter which direction the economy is going—that’s the secret that keeps you ahead in any market.
Think of it this way: if someone develops a cure for Alzheimer’s, it doesn’t matter what the market or economy is like.
That’s something that will be in demand. This is how the tech sector works and how you invest in it.
I’m proud of my accomplishments at Casey Extraordinary Technology.
And the success I’ve had in recommending a long list of cutting-edge stock winners to our Extraordinary Technology readers.
But the gains I’ve shown so far don’t hold a candle to the potential I believe is possible with this tiny biotech’s Alzheimer’s breakthrough…
Which is poised to skyrocket 1,000+% as mainstream investors get a whiff of its life-changing Alzheimer’s treatment.
But you need to move quickly…
Before the release of this company’s March 2014 clinical results…
Which could be possibly the single most important data readout on the subject of Alzheimer’s…
Because the results could indicate that this revolutionary new Alzheimer’s treatment shows as much promise in restoring memory and markedly improving learning skills within days in humans as it showed in previous clinical trials with laboratory mice.
After uncovering a sneak preview of what the biotech’s revolutionary treatment is capable of in Walter’s incredible story… I believe it will.
The March clinical results could cause a feeding frenzy among investors—the likes of which haven’t been seen since Pfizer and Merck introduced their all-time best-selling cholesterol, asthma, and erectile dysfunction drugs.
But none of these conditions was an untreatable top-10 killer of Americans like Alzheimer’s disease—plus, those companies were already mature and richly valued… that is to say, their shares were expensive.
This tiny company, on the other hand, could help save and improve millions upon millions of lives—and as I write this, its shares are still hovering around $11.28.
And here’s more good news: a recent new guideline by the FDA has created a faster pathway for Alzheimer’s treatments to make it to market.
Its “accelerated approval mechanism” allows demonstrated efficacy on a valid cognitive assessment to be sufficient for market approval, with follow-up studies required to show that the observed benefit persists.
In other words, this new guideline could significantly accelerate the pathway for commercialization for this company’s Alzheimer’s treatment.
You’ll get all the full details in my latest report: Extraordinary Wealth from Breakthrough Alzheimer’s Research… FREE—just for trying my research service, Casey Extraordinary Technology, risk-free.
Try Extraordinary Technology
for 90 Days… Risk-Free
Just subscribe today to Casey Extraordinary Technology, and if over the next 90 days you don’t think it’s worth at least 10 times its annual subscription price…
And if the market gains you could receive within 90 days, based on my recommendations, do not exceed at least 10X what you paid for your subscription…
Then please call Casey’s customer care team at 888-512-2739 and request your money back—ALL OF IT.
They will immediately credit your credit card with every penny you paid—no holdbacks, no restocking fees, no hard feelings, and no questions asked.
Now that’s well beyond fair, isn’t it?
The bottom line is, if you have a passion for technology—extraordinary, new technologies that are right now shaping the future… technologies that will benefit us all, regardless of the industry…
Be it in the aerospace and defense industry… the biotechnology and pharmaceutical industries… the medical device and healthcare industries… or in software, Internet services, computers, electronics, or robotics industries…
Then Casey Extraordinary Technology is for you.
Here’s All You’ll Get with Your Subscription
- 12 Monthly Editions of Extraordinary Technology—containing in-depth stock and company analyses that could run 30 pages or more. Every month you’ll learn about the very best technology plays and get at least one outstanding profit opportunity.
- Special Email Alerts—as many as 3 times per week, bringing you unusual or urgent opportunities, including buy recommendations, sell recommendations, and updates.
Technology Report #1:
Extraordinary Wealth from Breakthrough Alzheimer’s Research—Get the full details on a tiny biotechnology company that’s set to revolutionize the treatment for one of our most frightening diseases… Alzheimer’s. You could triple your investment in one day with this breakthrough treatment… or hold on a bit longer and potentially make gains of 769%… or more.
- Access to a library full of research at the Casey Research website—including newsletter archives and my extensively detailed status reports delivered weekly on companies I’m holding in the Casey Extraordinary Technology model portfolio.
- Iron-Clad Guarantee—You have 90 days to decide if Casey Extraordinary Technology is right for you, with a 100% refund if you decide to cancel during that period, or a prorated refund for the balance of my subscription if you should decide to cancel after the first 90 days.
Plus, if you subscribe right now, I’ll also send you a FREE video recording of my unedited presentation at the Casey Research Summit:
The Five Breakthrough Technologies
Reshaping the Economy
In this presentation, I detail exactly how, why, and when to invest in technology stocks.
In fact, I’ll show you on a graph the exact tipping point of when to invest in a technology company—when its technology is economically feasible on a mass scale.
Had you attended this summit, you would’ve paid $1,450 for your reserved seat.
You can still purchase a CD or MP3 recording of the entire summit for $395.
But if you subscribe right now to Casey Extraordinary Technology, my ‘breakthrough technologies’ presentation is yours absolutely FREE.
Which now brings us to what your subscription will run you…
The Casey Extraordinary Technology newsletter and alert service has a list price of just $995 per year.
Obviously, it’s not cheap.
Casey Extraordinary Technology is published exclusively for serious investors expecting serious gains.
Take action on any one of my recommendations and you could earn many times more than what you paid for your subscription—if not, ask for your money back.
Bottom line: Since we launched Casey Extraordinary Technology on July 20, 2009, our average return per closed position is 45%.
Bluntly put, you’d be hard pressed to find a technology newsletter that comes close to providing the gains Casey Extraordinary Technology does.
Subscribe to Casey Extraordinary Technology and immediately download your FREE copy of my report, Extraordinary Wealth from Breakthrough Alzheimer’s Research.
It’s an amazing investment opportunity that could turn your mere $10,000 investment into $107,690 after March, 2014…
Because that’s the earliest date the tiny biotech could release its highly anticipated results of the latest and most important clinical trial for its breakthrough “mind miracle” treatment.
And because I want as many readers as possible to have the opportunity to get an early-in on this transformational Alzheimer’s treatment, I’ve convinced my publisher to temporarily cut the subscription price to Casey Extraordinary Technology to only $700 per year.
That’s a huge 30% savings for you if you subscribe today.
And as an added bonus… if you subscribe by the middle of March, 2014, you will be locked in and guaranteed to never pay a penny more than $700 every time you renew your subscription.
In other words, for as long as you remain a subscriber, you will always be able to renew your subscription for just $700 per year.
I hope you agree that this is an extremely fair and generous offer—especially in light of all the valuable investment recommendations you’re about to receive.
So please, download my free report right now and join our family here at Casey Extraordinary Technology.
Remember: the technology sector has historically been a driver of enormous portfolio wealth, and there’s no doubt it could remain that way for years and years to come.
According to Gartner, Inc., the world’s largest information-technology research company, worldwide technology spending will soar to $3.8 trillion this year alone.
America was built on technology—and it will continue to thrive because of technology. Indeed, our future and fortunes depend on technology.
If you agree, then please join with me.
Just click the Subscribe Now button below…
And you’ll be taken to a secure webpage where you can enter your contact information so you can immediately receive your FREE report and video presentation.
To your ever-increasing wealth,
Editor in Chief, Casey Extraordinary Technology
Chief Technology Investment Strategist for Casey Research
P.S. For a limited time, you can get a risk-free trial of Casey Extraordinary Technology for only $700—nearly 30% off the list price. And you’ll get the bonus research report, Extraordinary Wealth from Breakthrough Alzheimer’s Research, absolutely FREE.
And remember, you’ll have 90 days to decide if this service is right for you. If it isn’t, you can let us know at any time during the 90 days to receive a prompt and full refund. Plus, you get to keep your free report no matter what you decide.
P.P.S. Extra Bonus: Act now and you’ll also receive a FREE video recording of my presentation at a Casey research summit: The Five Breakthrough Technologies Reshaping the Economy. From it, you’ll learn how, why, and when to invest in technology stocks.SUBSCRIBE NOW